King Rachel K. 4
4 · Fulcrum Therapeutics, Inc. · Filed Nov 14, 2024
Insider Transaction Report
Form 4
King Rachel K.
Director
Transactions
- Award
Stock Option (right to buy)
2024-11-12+60,000→ 60,000 totalExercise: $3.64Exp: 2034-11-11→ Common Stock (60,000 underlying)
Footnotes (1)
- [F1]This option was granted on November 12, 2024 and is scheduled to vest in equal monthly installments until November 12, 2027, subject to continued service.